Gerber Faces Continuing Antitrust Claims Over Infant Formula Factory Sale

A dispute over an infant formula manufacturing plant reached an important stage in federal court on September 18, 2026. A New York federal judge declined to dismiss key antitrust allegations against Gerber Products Company, allowing claims concerning the company's sale of an infant formula factory to continue. The decision keeps attention on competition in a market where manufacturing capacity can play a major role in determining which companies can effectively compete.

The Gerber infant formula antitrust case is pending in the United States District Court for the Eastern District of New York. P&L Development, LLC, known as PLD, alleges that Gerber's conduct surrounding the sale of its Gateway infant formula manufacturing facility helped protect the market position of Perrigo, a major supplier of store brand infant formula. Gerber disputes the allegations, and the court's ruling does not establish that the company violated antitrust law.

Federal Court Allows Antitrust Allegations To Proceed

The September 18 ruling centered on whether PLD had adequately stated its allegations against Gerber at this stage of the litigation. United States District Judge Nina Gershon concluded that the amended complaint contained sufficient allegations concerning the economic purpose and competitive effects of the factory acquisition.

PLD has alleged that Gerber's sale of its infant formula manufacturing facility increased barriers for companies seeking to compete in the store brand formula market. The case concerns the Gateway facility in Wisconsin, which Gerber previously used to manufacture infant formula.

According to the allegations, PLD had entered into a memorandum of understanding under which Gerber would supply it with infant formula. PLD planned to use that supply as part of an effort to compete in the store brand market. The litigation alleges that Gerber later moved away from that arrangement and ultimately sold the manufacturing facility to Perrigo.

The antitrust allegations focus on what that transaction allegedly meant for competition. PLD contends that the sale limited access to manufacturing capacity and made it more difficult for potential competitors to enter or expand in the store brand infant formula business.

The court's decision allows those claims to move forward. However, that procedural result is important to distinguish from a final determination on the merits. Allowing a claim to proceed means the allegations have cleared the applicable legal threshold at this stage. It does not mean that the allegations have been proven.

Why Manufacturing Capacity Matters In The Case

The dispute highlights an important feature of competition law. Courts evaluating antitrust claims may examine more than prices or market shares. They can also consider whether business transactions affect a potential competitor's practical ability to enter a market.

Manufacturing infrastructure can be particularly significant when entering a market requires specialized facilities, regulatory compliance, technical expertise, and substantial investment. A company that wants to compete may face greater barriers if suitable manufacturing capacity is limited.

That issue sits at the center of PLD's allegations. The company contends that the Gateway transaction strengthened Perrigo's market position while reducing opportunities for potential rivals. Gerber has challenged the claims through the litigation process.

The broader dispute has involved Perrigo Company plc, L. Perrigo Company, and PBM Nutritionals, LLC as defendants alongside Gerber. Perrigo disclosed in a 2026 regulatory filing that it reached an agreement in principle with PLD and plaintiffs in related litigation to settle claims against the Perrigo defendants. At the time of that disclosure, the parties were preparing final settlement agreements.

The proceedings involving Gerber have continued separately. Perrigo's settlement developments do not establish liability by Gerber and do not resolve the remaining allegations against it.

A Wider Antitrust Question For Consumer Markets

The Gerber infant formula antitrust case offers a useful example of how federal competition law can apply to transactions involving production assets.

Antitrust disputes often attract attention when companies pursue major mergers or acquisitions. Yet competition questions can also arise from the transfer of an individual factory or other strategically important asset. If an asset is difficult to replace and essential for market entry, control over that resource can become relevant to an analysis of competitive conditions.

For businesses, the case underscores why transactions involving manufacturing facilities may receive legal scrutiny beyond conventional questions about ownership and purchase price. Courts can be asked to consider whether an agreement or asset transfer allegedly restricts competition or reinforces existing market power.

For consumers, the litigation is relevant because store brand products generally compete alongside nationally recognized brands. The legal dispute does not establish that the factory sale caused consumers to pay higher prices. Instead, the case will continue examining allegations about whether the transaction improperly restricted competition in the relevant market.

What Comes Next In The Gerber Case

The September 18 decision keeps the dispute alive rather than resolving it. The parties can continue developing their evidence as the litigation progresses, and later proceedings may address the factual record in greater detail.

That distinction is crucial for understanding federal litigation. A decision denying dismissal is not a finding of wrongdoing. Plaintiffs still carry the burden of supporting their allegations through the legal process, while defendants retain opportunities to challenge the claims and evidence.

For legal professionals and businesses, the case is worth watching because it places manufacturing access at the heart of an antitrust dispute involving a major consumer product. The ultimate outcome could provide additional insight into how federal courts evaluate allegations that the transfer of a critical production asset created barriers for potential competitors.

For now, the September 18 ruling establishes one clear procedural development: the challenged antitrust allegations against Gerber remain before the federal court, and the dispute over competition in the store brand infant formula market will continue.